Medtronic has announced CE Mark approval and the launch of its NC Euphora noncompliant balloon dilatation catheter.


With the CE Mark approval, the NC Euphora balloon catheter is now available in Europe and other countries outside of the US that recognize the CE Mark.

Conquest Hospital Hastings and Eastbourne District General Hospital East Sussex Healthcare NHS Trust consultant interventional cardiologist, and pre-clinical researcher for the NC Euphora balloon Dr Robert Gerber said that when using a noncompliant balloon, deliverability and re-cross are important characteristics, especially when faced with challenging coronary anatomy.

"The NC Euphora balloon was designed to meet these demands and provide reliable performance with no tradeoffs in the moment that we need it most," Dr Gerber added.

The NC Euphora Balloon Catheter features PowerTrac technology, an optimized tapered tip design and low lesion entry profile, durable and flexible LIGHT (Low Inflation Growth, High Track) balloon material, and superior growth profile.

PowerTrac technology provides superior deliverability through tight lesions and requires less force to track through tortuous anatomy.

The tapered tip design and low lesion entry profile improves flexibility and allows for reliable stent re-cross when traversing long, challenging lesions so that the balloon does not catch on a strut when passing through a deployed stent.

The LIGHT balloon material provides high pressure capability, which enables NC Euphora to expand consistently within the stent area at a rated burst pressure of up to 20 atmospheres without bursting.

NC Euphora provides superior growth profile with significantly low radial growth to reduce unwanted vessel expansion and low longitudinal growth beyond the stent length to minimize damage to the surrounding healthy artery.

According to Medtronic, NC Euphora expands the company’s interventional portfolio of medical devices across coronary, renal denervation and transcatheter aortic-valve implantation. The device is the latest in a series of 12 new product introductions planned over the next two years.

Image: Medtronic’s world headquarters in Minneapolis, US. Photo: Courtesy of Medtronic, Inc.